Possible different genotypes for human papillomavirus vaccination in lower middle-income countries towards cervical cancer elimination in 2030: a cross-sectional study.
Tofan Widya UtamiAndrijono AndrijonoAndi D PutraJunita IndartiGert FleurenEkaterina S JordanovaInas HumairahAhmad Rusdan Handoyo UtomoPublished in: Clinical and experimental vaccine research (2022)
This study suggested beneficial screening for women aged 31-50 years old. Instead of "original" nonavalent (HPV 16, 18, 6, 11, 31, 33, 45, 52, 58), the different "nonavalent" formula for HPV vaccines protecting against HPV 16, 18, 6, 11, 31, 39, 44, 52, 74 might be useful for Indonesian population. However, further multicenter studies with a huge sample size are still needed.